Fig. 4: PG16-Db and 3BNC117-Db eliminate cells harboring intact proviruses when paired with strong latency reversal.

a, Frequency of intact provirus⁺ CD4⁺ T cells after treatment with no LRA, bryostatin, AZD5582, romidepsin, SAHA, CD3 + CD28 antibodies or PMA + I and coculture with autologous NK cells in the presence of H2-Db, PG16-Db, 3BNC117-Db or PG16-Db + 3BNC117-Db. Data are reported as intact HIV-1 copies per million viable CD4⁺ T cells (mean, s.d.) from eight replicates. The significance was determined by two-way ANOVA followed by Dunnett’s test for multiple comparisons: ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001. b, Expression of caRNA after treatment with LRAs as in a. Data are reported as caRNA copies per million CD4⁺ T cells (mean, s.d.) from three replicates. The significance was determined by one-way ANOVA followed by Dunnett’s test for multiple comparisons: ^***P < 0.001, ^****P < 0.0001. c, Correlation between percentage reduction in intact copies and mean fold-change in caRNA. Spearman’s r value is shown.